secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001854270-23-000088
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio sells manufacturing assets to GeneFab for ~$38M cash; extends cash runway to Q4 2024
--------------------------------------------------------------------------------

- Sold Alameda cGMP facility and CMC capabilities to GeneFab (backed by Celadon Partners) for ~$38M cash with deferred payments, plus $8M manufacturing credit.
- Transaction extends cash runway into Q4 2024; SENTI-202 IND remains on track for 2H 2023.
- CTO Philip Lee resigns to become CEO of GeneFab; ~35% of Senti employees transition to GeneFab.
- GeneFab receives option to invest up to $20M in Senti common stock at $1.01867/share over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000088/0001854270-23-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000088/snti-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer